Incyclinide (CollaGenex) gets NIH Funding

Written by on November 10, 2005 in tetracyclines with 1 Comment

Formerly known as COL-3, Incyclinide is a chemically modified tetracycline, modified to retain non-antibiotic properties that may make them effective in treating diseases involving inflammation and/or destruction of the body’s connective tissues.

CollaGenex have announced that the National Institutes of Health (“NIH”) has awarded a grant of approximately $962,000 for additional research into the potent anti-inflammatory effects of incyclinide.

The grant will be paid over two years and will support CollaGenex’s manufacturing and formulation development of incyclinide as well as preclinical studies. This will further enable researchers to “conduct additional studies that should advance the Company’s understanding of incyclinide’s potent anti-inflammatory properties”.

“In clinical studies of patients with Kaposi’s sarcoma and rosacea, we saw dramatic improvements in these inflammatory disorders in patients administered incyclinide. This NIH grant will help us better understand incyclinide’s mechanisms of action and its potential to treat acute inflammatory conditions.”

Related Articles:

Read more about: tetracyclines

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

1 Reader Comment

  1. Joan N. says:


    What ever happened to all of the grant money that the National Institute of Health donated to Collagenex (I think it was around $1,000,000) to help develop Incyclinide? I heard that the drug failed for long-term Rosacea treatment and they were stopping production of the drug for Acne clinical trials. So now, where is that money, lining some CEO’s pocket at that company?

    Those of us who suffer from Rosacea get awfully tired of seeing one shining light after another snuffed out for a possible cure for this disease.

    March 2008

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.